Mode
Text Size
Log in / Sign up
N/A N=4 Treatment

Computer-Assisted Rehabilitation Environment Training After Argus Retinal Prosthesis

Retinitis Pigmentosa

Enrolled (actual)
4
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcome: Primary: Effects of CAREN Virtual Reality System on Obstacle Course Navigation — 51.25; 33.75 seconds

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
CAREN system training (Device)
Age
Adult, Older Adult · 25+ yrs
Sex
All
Sponsor
The Cleveland Clinic
Primary completion
Jun 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Effects of CAREN Virtual Reality System on Obstacle Course Navigation
51.25; 33.75
PRIMARY
Time to Complete the Timed Up and Go Test Before and After CAREN Virtual Reality System Training
52.8; 39.29
PRIMARY
Effects of CAREN Virtual Reality System on Square Localization Visual Function Test
274.62; 245.43
PRIMARY
Effects of CAREN Virtual Reality System on Direction of Motion Visual Function Test.
65.68; 58.12
PRIMARY
Effects of CAREN Virtual Reality System on Grating Visual Acuity Visual Function Test
2.53
PRIMARY
Effects of CAREN Virtual Reality System on Gait Assessment
111.05; 130.7

Summary

The goal of the current project is to fill the unmet clinical needs around the objective assessment of visual function and develop outcome-oriented visual rehabilitation approach using the computer assisted rehabilitation environment (CAREN) system for Argus recipients.

Eligibility Criteria

Inclusion Criteria

  • Recipient of the Argus II Retinal Prosthesis System
  • Ability to provide informed consent
  • Ability to follow two-step commands
  • Ability to ambulate 300+ feet with or without visual assistance
  • Able to tolerate Argus device turned on for >20 continuous minutes.

Exclusion Criteria

  • Dementia
  • Musculoskeletal contraindication to exercise or walking
  • Cardiopulmonary contraindication exercise (i.e. uncontrolled heart failure, cardiac arrhythmia, or pulmonary disease).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03444961). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search